TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23377511
Drug: Clindamycin 1.2%‐tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 1.2%‐tretinoin 0.025% (CLIN/RA) gel
Study: 23377511
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 2.5%‐adapalene 0.1% (BPO/ADA) gel
Study: 19020122
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg dexamethasone (Group D1)
Study: 19020122
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg dexamethasone (Group D2)
Study: 12614528
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (historic control)
Study: 10403616
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg once daily)
Study: 10403616
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg once daily)
Study: 7720941
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (3.75 mg IM leuprolide acetate every 28 days for 6 months)
Study: 7720941
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (combination monophasic for 6 months)
Study: 7720941
Drug: Combination GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination GnRH agonist and oral contraceptive (LA + OC for 6 months)
Study: 30796919
Drug: Specialized Physical
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized Physical Therapy (SPT)
Study: 30796919
Drug: Regular Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Physical Therapy (RPT)
Study: 27631821
Drug: Short-term dual
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dual antiplatelet therapy (DAPT) (6 months or less)
Study: 27631821
Drug: Prolonged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dual antiplatelet therapy (DAPT) (12 months or more)
Study: 24760352
Drug: 3.1% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.1% sodium chloride solution (hypertonic saline)
Study: 21537493
Drug: p-synephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (50 mg)
Study: 21537493
Drug: p-synephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (50 mg) + naringin (600 mg)
Study: 21537493
Drug: p-synephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (100 mg)
Study: 21537493
Drug: p-synephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (1000 mg)
Study: 19616143
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control group (n=42)
Study: 17162192
Drug: Allopurinol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (40 mg/kg/day, 3 days)
Study: 15167086
Drug: Parent-infant home-visiting
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-infant home-visiting services (0 to 18 months of weekly visits)
Study: 8071511
Drug: Supplemental nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental nasal oxygen (2 l/min)
Study: 2647817
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 IU in a bolus injection)
Study: 4426706
Drug: C14‐S5 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: C14‐S5 strain with varying doses
Study: 26061762
Drug: 10% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% maltodextrin solution (CHO)
Study: 23863810
Drug: pioglitazone (PGZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (PGZ; 45 mg/day)
Study: 19519298
Drug: Gefitinib or
Normalized name: gefitinib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib or Erlotinib in combination with chemotherapy
Study: 9412258
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol (5‐8 mg/kg.h)
Study: 9412258
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion regimen
Study: 7682167
Drug: Conventional enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enteric-coated tablet of diclofenac sodium 50 mg orally, thrice daily
Study: 3806153
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (thiazide diuretic and propranolol if needed)
Study: 3806153
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal preparation (mixture of 12 herbs)
Study: 27771274
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) administered 3 times a day for 2 consecutive days, each cycle lasting 1 to 3 hours
Study: 27771274
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (oxygen, early mobilization, a program of breathing exercises and diuretics)
Study: 23570299
Drug: Peroxide bleaching
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroxide bleaching gel Opalescence PF 20, treated 25 times for eight hours per day.
Study: 23570299
Drug: Peroxide bleaching
Normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroxide bleaching gel Opalescence PF 20.
Study: 22118569
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high-MW oat β-glucan (3H, n = 67)
Study: 22118569
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g medium-MW oat β-glucan (4M, n = 50)
Study: 22118569
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g medium-MW oat β-glucan (3M, n = 54)
Study: 22118569
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g low-MW oat β-glucan (4L, n = 51)
Study: 17022023
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of infertility (physician diagnosis, prescription for infertility medication, or evaluation at infertility clinics)
Study: 17022023
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of clomiphene citrate within 60 days before to 15 days after conception
Study: 17022023
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prescription of clomiphene citrate)
Study: 15163330
Drug: Nutritional programme
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional programme (12 mg/day iron and 6000 IU/week vitamin A)
Study: 15163330
Drug: Oxandrolone therapy
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone therapy (5 mg/day for 6 months)
Study: 15163330
Drug: Testosterone depot
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone depot (100 mg monthly for 3 months or 6 months)
Study: 2889306
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of SMS 201-995 (50 micrograms and 100 micrograms a day)
Study: 2889306
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of SMS 201-995 (100 micrograms)
Study: 2889306
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of SMS 201-995
Study: 2889306
Drug: Multiple subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple subcutaneous injections of SMS 201-995 (100 micrograms each)
Study: 27351628
Drug: Everolimus (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4.5 mg/m2/day, titrated to a target blood trough of 5-15 ng/mL)
Study: 22715833
Drug: Cold air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold air application in palm injections
Study: 20501394
Drug: BUMA drug-eluting
Normalized name: Bumadizone
DrugBank: Bumadizone (DB13286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUMA drug-eluting stent
Study: 20129543
Drug: Endeavor drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endeavor drug-eluting stent
Study: 3310017
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sodium hyaluronate
Study: 30077383
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with ultra-wide 7-mm-diameter implants
Study: 30077383
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement in molar healed sites after socket preservation
Study: 21492416
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg/dose) administered once weekly for three doses
Study: 21492416
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once weekly for three doses
Study: 15232360
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg twice daily for 7 days
Study: 15232360
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg 4 times daily for 5 days
Study: 8201970
Drug: Theophylline (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (IV bolus of 220 mg followed by IV infusion of 1 mg/kg/h)
Study: 3354399
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (230 patients)
Study: 3354399
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (218 patients)
Study: 21199268
Drug: Glimepiride (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (starting dose 1 mg/day, max 6 mg/day)
Study: 16713501
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration study with feedback and information about harmful effects
Study: 16713501
Drug: Alcohol administration
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol administration study
Study: 12898439
Drug: intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent subcutaneous IL-2 and placebo
Study: 12898439
Drug: intermittent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: intermittent subcutaneous IL-2 and prednisone
Study: 7602215
Drug: MDT +
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDT + BCG (rifampin once a month, clofazimine and dapsone daily, BCG intradermally 0.1 mg/dose)
Study: 7602215
Drug: MDT +
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDT + Mycobacterium w (same MDT with 2 x 10(8) killed bacilli/dose i.d.)
Study: 31864519
Drug: Individualized rehabilitation
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized rehabilitation and chiropractic treatment
Study: 18641526
Drug: Debridement twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement twice a week (Group 1)
Study: 16875473
Drug: TAC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (10 mg/mL) injected weekly for 8 weeks
Study: 16875473
Drug: TAC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (40 mg/mL) + 5-FU (50 mg/mL) injected weekly for 8 weeks
Study: 16875473
Drug: TAC (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAC (40 mg/mL) + 5-FU (50 mg/mL) injected weekly for 8 weeks + PDL (5-7.5 J/cm2) at 1st, 4th, and 8th weeks
Study: 10718774
Drug: 10 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg, 20 mg, and 10 + 20 mg tablets; solution administered once daily for 2 weeks
Study: 14584871
Drug: One-stage full-mouth
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage full-mouth scaling and root planing (FMSRP) plus amoxicillin/clavulanic acid 875 mg (G1)
Study: 11469284
Drug: Early occupational
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early occupational therapy intervention, given weekly at home from six months to 12 months.
Study: 28126333
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy (cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2 every 3 weeks for four cycles followed by maintenance pemetrexed)
Study: 26432173
Drug: Therapy process
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy process at the end stage
Study: 23239676
Drug: Beta-alanine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine (80 mg · kg‐1 BM · d‐1)
Study: 18287411
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (PEI) + radiofrequency ablation (n = 50)
Study: 16541860
Drug: Oral Biyankang,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Biyankang, 4 tablets each time, 3 times daily
Study: 18178950
Drug: Polysporin Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysporin Triple antibiotic ointment
Study: 8944697
Drug: Telenzepine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine (selective M1-receptor antagonist)
Study: 6758743
Drug: Labetalol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (twice daily dosage)
Study: 31594196
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy at -110°C with exercise therapy
Study: 31594196
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy at -60°C with exercise therapy
Study: 12875346
Drug: Current oral
Normalized name: black currant oil Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current oral suspension
Study: 12875346
Drug: Former oral
Normalized name: Triple Wormer Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Former oral suspension
Study: 10505695
Drug: Eicosapentanoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentanoic acid (EPA) at a dose of 1800 mg daily for 3 months
Study: 7559196
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg bd iv)
Study: 7559196
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (ceftazidime 1 g bd iv, ampicillin 500 mg qds iv, metronidazole 500 mg tds iv)
Study: 31970564
Drug: PBM therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM therapy with a CW GaAIAs diode laser (808 nm; 0.028 mm2; 0.1 W; 3.6 W/cm2; 89 J/cm2; 2.5 J/point)
Study: 29021311
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment arm (n=30)
Study: 29021311
Drug: Emergency endovascular
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency endovascular treatment of the extracranial disease (n=17)
Study: 29021311
Drug: Antithrombotic agents
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic agents after acute carotid artery stenting
Study: 17094088
Drug: Sarizotan 2
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan 2 mg/day
Study: 17094088
Drug: Sarizotan 10
Normalized name: Sarizotan
DrugBank: Sarizotan (DB06454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan 10 mg/day
Study: 17094088
Drug: Sarizotan (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarizotan (2, 4, or 10 mg/day)
Study: 15733882
Drug: 1-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g oral dose of secnidazole (n=44)
Study: 15733882
Drug: 2-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g oral dose of secnidazole (n=32)
Study: 15733882
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of secnidazole
Study: 11315503
Drug: Red palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red palm oil (90 mg beta-carotene)
Study: 11315503
Drug: Beta-carotene supplements
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplements
Study: 9252738
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate emollient 0.05 percent, 0.43 to 0.5 gm twice daily for four weeks
Study: 9252738
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate emollient, 1.5 gm applied twice daily for seven consecutive days
Study: 30220621
Drug: Laser groove
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser groove treatment (100μm-deep, 150μm-deep, 200μm-deep)
Study: 30220621
Drug: Air abrasion
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air abrasion treatment
Study: 28150850
Drug: Chewing 180
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing 180 mg ticagrelor
Study: 28150850
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral 180 mg ticagrelor
Study: 24222836
Drug: Eptifibatide infusion
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide infusion <10 hours
Study: 24222836
Drug: Eptifibatide infusion
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide infusion 10-17 hours
Study: 24222836
Drug: Eptifibatide per-protocol
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide per-protocol infusion (18-24 hours)
Study: 15258349
Drug: Aspirin (100-325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100-325 mg/d)
Study: 11419768
Drug: Diabetes recall
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes recall system established at eight of the 21 sites, staff training in basic diabetes care, regular phone calls from the project officer, a two‐monthly newsletter and a mid‐project workshop.
Study: 9438089
Drug: Saline containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline containing a low dose of epinephrine (50 ml, diluted to 1:200,000) with drain clamping for 20 hours
Study: 9438089
Drug: Saline only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline only (50 ml) with drain clamping for 20 hours
Study: 3435365
Drug: Ibuprofen 400mg
Normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400mg tablet at the first sign of pain or bleeding, followed by 400mg every 4 to 6 hours for the duration of expected symptoms
Study: 26200403
Drug: Control (Enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Enoxaparin Monotherapy)
Study: 23306362
Drug: Prototype vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype vaccine containing LCTBA and CFA/I overexpressing E. coli
Study: 23306362
Drug: Prototype vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype vaccine (higher dose)
Study: 23306362
Drug: Reference vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference vaccine (CTB and inactivated wild type ETEC bacteria expressing CFA/I)
Study: 21688030
Drug: HHD group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HHD group (4% succinylated gelatin infused at 20 ml•kg(‐1)BW•h(‐1) with targeted hematocrit of 30)
Study: 12640221
Drug: Risperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5 mg/day, increased up to 2.0 mg/day based on response)
Study: 7862905
Drug: Fluoxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (n = 22)
Study: 1233188
Drug: Depot heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot heparin (Calciparin)
Study: 15105387
Drug: Electro-acupuncture (EA)
Normalized name: ELECTRODE SPRAY,ELECTRO MIST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (EA) in combination with a paracervical block (PCB) (n = 100)
Study: 15105387
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical analgesia (CMA) in combination with a PCB (n = 100)
Study: 7717792
Drug: Structured sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured sleep hygiene with early morning light therapy
Study: 1781822
Drug: Nonionic agents
Normalized name: LANOLIN DERIVATES,NONIONIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic agents (ioxaglate, iohexol)
Study: 1781822
Drug: Ionic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic agent (Renografin‐76)
Study: 24153331
Drug: Intervention (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (not specified in detail, but implied to be treatment for JCCP)